CA125在心血管疾病中作用的研究进展

摘要/Abstract

摘要： 碳水化合物抗原125（CA-125）是一种糖蛋白抗原,主要用于卵巢恶性肿瘤筛查、诊断和监测的肿瘤标志物。近年来研究发现CA125与多种心血管疾病（CVD）相关。本文就CA125在CVD中的作用研究进展作一综述。

庞樱容, 孙欣. CA125在心血管疾病中作用的研究进展[J]. 心血管病防治知识, 2024, 14(8): 141-144.

[1] Virani SS, Alonso A, Benjamin EJ, et al.Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association[J]. Circulation, 2020, 141(9): e139-e596.
[2] Clarke-Pearson DL.Clinical practice. Screening for ovarian cancer[J]. The New England Journal of Medicine, 2009, 361(2): 170-177.
[3] Falcão F, De Oliveira FRA, Da Silva MCFC, et al.Carbohydrate antigen 125: a promising tool for risk stratification in heart diseases[J]. Biomarkers in Medicine, 2018, 12(4): 367-381.
[4] Núñez J, De la Espriella R, Miñana G, et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review[J]. European Journal of Heart Failure, 2021, 23(9): 1445-1457.
[5] Ferreira JP, Packer M, Sattar N, et al.Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme[J]. European Journal of Heart Failure, 2024.
[6] Feng R, Zhang Z, Fan Q.Carbohydrate antigen 125 in congestive heart failure: ready for clinical application?[J]. Frontiers in Oncology, 2023, 13: 1161723.
[7] Llàcer P, Gallardo MÁ, Palau P, et al.Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure[J]. MedicinaClinica, 2021, 156(12): 589-594.
[8] Núñez J, Bayés-Genís A, Revuelta-López E, et al.Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure[J]. Revista Espanola De Cardiologia (English Ed.), 2022, 75(4): 316-324.
[9] Docherty KF, McDowell K, Welsh P, et al. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure[J]. Journal of the American College of Cardiology, 2023, 82(2): 142-157.
[10] Miñana G, De la Espriella R, Palau P, et al. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction[J]. Scientific Reports, 2022, 12(1): 1344.
[11] Menghoum N, Badii MC, Deltombe M, et al.Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction[J]. ESC heart failure, 2024.
[12] Ferreira JP, Packer M, Sattar N, et al.Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme[J]. European Journal of Heart Failure, 2024.
[13] Núñez J, Llàcer P, Bertomeu-González V, et al.Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study[J]. JACC. Heart failure, 2016, 4(11): 833-843.
[14] Miñana G, De la Espriella R, Mollar A, et al. Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure[J]. European Heart Journal. Acute Cardiovascular Care, 2020, 9(5): 437-447.
[15] Kirchhof P, Benussi S, Kotecha D, et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery, 2016, 50(5): e1-e88.
[16] Liao X, Li S, Yan X, et al.Association of preoperative CA-125 levels with early POAF after heart valve surgery: a single-center, retrospective study[J]. BMC Surgery, 2023, 23.
[17] Cheung A, Gong M, Bellanti R, et al.Cancer antigen-125 and risk of atrial fibrillation: a systematic review and meta-analysis[J]. Heart Asia, 2018, 10(1): e010970.
[18] Vizzardi E, D’Aloia A, Curnis A, et al. Carbohydrate antigen 125: a new biomarker in heart failure[J]. Cardiology in Review, 2013, 21(1): 23-26.
[19] Sekiguchi H, Shimamoto K, Takano M, et al.Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women[J]. Heart (British Cardiac Society), 2017, 103(17): 1368-1373.
[20] Yucel H, Kaya H, Zorlu A, et al. Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation[J]. Herz, 2015, 40 Suppl 2: 119-124.
[21] Asad ZUA, Yousif A, Khan MS, et al.Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J]. Circulation. Arrhythmia and Electrophysiology, 2019, 12(9): e007414.
[22] Deftereos SG, Vrachatis DA, Angelidis C, et al.The Role of Colchicine in Treating Postoperative and Post-catheter Ablation Atrial Fibrillation[J]. Clinical Therapeutics, 2019, 41(1): 21-29.
[23] Huang Z, Liang X, Wang W, et al.Relationship between plasma cancer antigen (CA)-125 level and one-year recurrence of atrial fibrillation after catheter ablation[J]. ClinicaChimica Acta; International Journal of Clinical Chemistry, 2020, 502: 201-206.
[24] Wang Q, Dang C, Liu H, et al.Plasma carbohydrate antigen-125 for prediction of atrial fibrillation recurrence after radiofrequency catheter ablation[J]. BMC cardiovascular disorders, 2021, 21(1): 400.
[25] Ding Y, Wang Q, Yang Y, et al.[Diagnostic value of copeptin and cancer antigen 125 in acute heart failure patients with atrial fibrillation and their correlations with short-term cardiovascular events] [J]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 2018, 30(11): 1024-1028.
[26] Witkowska A, Staciwa M, Duraj I, et al.Interleukin-33/sST2: Dynamic assessment in patients with acute coronary syndrome[J]. Advances in Medical Sciences, 2023, 68(2): 195-201.
[27] Zhang R, Jin W, Han M, et al.Carbohydrate antigen 125 in atrial fibrillation[J]. ClinicaChimica Acta, 2023, 549: 117550.
[28] Sang GY, Chen ZY, Meng CR, et al.Serum Tumor Marker Carbohydrate Antigen 125 Levels and Carotid Atherosclerosis in Patients with Coronary Artery Disease[J]. Open Medicine (Warsaw, Poland), 2018, 13: 534-538.
[29] Li X, He M, Zhu J, et al.Higher carbohydrate antigen 125 levels are associated with increased risk of coronary heart disease in elderly chinese: a population-based case-control study[J]. PloS One, 2013, 8(11): e81328.
[30] Wallentin L, Eriksson N, Olszowka M, et al.Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study[J]. PLoS Medicine, 2021, 18(1): e1003513.
[31] Xu K, Wu M, Huang M, et al.Carbohydrate antigen 125 combined with N-terminal pro-B-type natriuretic peptide in the prediction of acute heart failure following ST-elevation myocardial infarction[J]. Medicine, 2022, 101(48): e32129.
[32] Falcão F, Oliveira F, Cantarelli F, et al.Carbohydrate antigen 125 for mortality risk prediction following acute myocardial infarction[J]. Scientific Reports, 2020, 10(1): 11016.
[33] De Gennaro L, Brunetti ND, Bungaro R, et al.Carbohydrate antigen-125: additional accuracy in identifying patients at risk of acute heart failure in acute coronary syndrome[J]. Coronary Artery Disease, 2009, 20(4): 274-280.
[34] Falcão FJA, Oliveira FRA, Cantarelli F, et al.Carbohydrate antigen 125 predicts pulmonary congestion in patients with ST-segment elevation myocardial infarction[J]. Brazilian Journal of Medical and Biological Research, 2019, 52(12): e9124.
[35] Zhang Y, Jin Q, Zhao Z, et al.Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension[J]. Frontiers in Cardiovascular Medicine, 2021, 8.
[36] Sahin A, Kaya H, Avci O.Cancer antigen-125 is a predictor of mortality in patients with pulmonary arterial hypertension[J]. Clinical Biochemistry, 2021, 89: 58-62.

CA125在心血管疾病中作用的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王洋洋, 李晓慧, 彭阳. 单核细胞与高密度脂蛋白比值、血清甲状旁腺激素、载脂蛋白A1、胱抑素C及同型半胱氨酸水平与急性心肌梗死患者合并心力衰竭的相关性研究[J]. 心血管病防治知识, 2024, 14(8): 41-43.
[2]	童慧玲, 陈亮. 恩格列净联合沙库巴曲缬沙坦对慢性心力衰竭合并2型糖尿病患者心功能的影响[J]. 心血管病防治知识, 2024, 14(8): 44-47.
[3]	张守艳, 陈丹凤, 林榕. IMPACT模式护理对慢性射血分数保留心力衰竭患者遵医优良率的改善效果[J]. 心血管病防治知识, 2024, 14(8): 116-119.
[4]	叶斯敏, 苏秋园, 黄容容, 黄爱琴, 施桂玲. 脚踏车结合运动康复训练对冠心病心衰患者心功能及自我管理行为分析[J]. 心血管病防治知识, 2024, 14(7): 74-77.
[5]	许銮仙. 渐进性康复护理对重症监护室心力衰竭患者心功能及效果分析[J]. 心血管病防治知识, 2024, 14(7): 94-96.
[6]	谢陈霞, 翁小清. 基于运动的心脏康复护理方案对老年慢性心力衰竭患者心功能及康复效果的影响[J]. 心血管病防治知识, 2024, 14(7): 97-100.
[7]	王金玉. 针对性护理对老年慢性心力衰竭重症患者营养状况的干预效果评价[J]. 心血管病防治知识, 2024, 14(7): 104-106.
[8]	曾翠峰. 心力衰竭早期预警配合运动康复训练在冠心病合并慢性心力衰竭中的应用效果观察[J]. 心血管病防治知识, 2024, 14(7): 123-127.
[9]	薛培钰, 顾小英, 杨燕. 高血压并老年心力衰竭患者应用多元化延续性护理的效果分析[J]. 心血管病防治知识, 2024, 14(7): 128-131.
[10]	张希坤. 慢性心力衰竭患者急性发作期HS-CRP、NT-proBNP的表达及与预后的相关性研究[J]. 心血管病防治知识, 2024, 14(5): 7-11.
[11]	黄小丽. 达格列净联合沙库巴曲缬沙坦钠对顽固性慢性心力衰竭患者心损标志物及神经内分泌因子的影响[J]. 心血管病防治知识, 2024, 14(5): 35-37.
[12]	冯玲华. 贝那普利、沙库巴曲缬沙坦分别治疗HFpEF对患者血清cTnI、H-FABP水平的影响[J]. 心血管病防治知识, 2024, 14(5): 38-41.
[13]	卓红微, 黄大鑫. 血府逐瘀汤联合盐酸贝那普利片对心血瘀阻型慢性心力衰竭患者的临床疗效[J]. 心血管病防治知识, 2024, 14(5): 49-52.
[14]	罗燕萍. 基于分期精细化容量管理的护理干预对急性心力衰竭患者急救效率及不良事件风险分析[J]. 心血管病防治知识, 2024, 14(5): 107-111.
[15]	黄海, 黄平. 赋能理论下改良护理模式对心力衰竭患者自我护理能力及生活质量的影响[J]. 心血管病防治知识, 2024, 14(5): 115-117.